>>Outrageous claims of potential gains here and aiding and abetting pumpers are frowned upon.
Let's look at what you seem to think is pumping every time I post a possible future valuation. Humira arns $8 billion annually (yeah, that's a lot of dough). If Prurisol does in humans what it did in animals, and once Humira goes generic in 2 years, CTIX will capture at least all of that market. Standard for Phase 3 positive outcome is 20% royalty or better in a license, 50% profit share in a partnership. That's 1.6 billion in revenue with no further expenditures. At a conservative 10X earnings CTIX market cap is $16 billion, or more than $100 a share.
Add Kevetrin to that, and if it reaches market it will be within 2 years, since you seem to agree that Kevetrin is binary, it either results in p53 repair or doesn't, yes? Even if it does not work alone, it will become standard therapy in combination with other current and future drugs. Taking again a conservative approach and assuming it only penetrates 25% (out of 50% of all tumors) then we have 25% of 50 billion global sales or about $12 billion. Again we can easily assume a minimum of 20% royalty which yield annual revenue of 2.5 billion. See where this is going?
This isn't pumping; these are the facks Jack.
